In the course of evaluating the optimal duration of bisphosphonate treatment the FDA found little benefit of treatment beyond 5 years. [1,2] Moreover, examination of studies where bisphosphonates ...

The FDA has approved two new biosimilars of denosumab-dssb to treat osteoporosis, increase bone mass, prevent ...

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. These highlights do not include all the information needed to use XBRYK safely and effectively. See full prescribing ...

Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...

ALP is an enzyme found in the blood that helps break down proteins. It plays a role in numerous processes in the human body, and any abnormalities in blood concentrations—either high or low—may ...